

Juvenile Idiopathic Arthritis

Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis

Trial Status
Completed

Trial Runs In
12 Countries

Trial Identifier
NCT02165345 2013-005212-98
WA29231

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This open-label extension of the JIGSAW studies (WA28117 [NCT01904279] and WA28118 [NCT01904292]) is designed to evaluate the long-term safety and efficacy of subcutaneous (SC) tocilizumab treatment in participants with polyarticular-course and systemic juvenile idiopathic arthritis (pJIA and sJIA). Participants from the 2 JIGSAW studies will continue to receive 162 milligrams (mg) of SC tocilizumab with treatment schedule according to arthritis subtype and body weight. Participants will receive the treatment until commercial availability of the drug or for a maximum of 5 years, whichever is earlier.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT02165345 2013-005212-98 WA29231
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=2 Years & <= 18 Years

Healthy Volunteers
No